Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Pioglitazone in ADPKD
NCT02697617Phase 2Completed
- Sponsor
- Indiana University
- Start
- Jan 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Pioglitazone Arm with Placebo Arm (2 arms). Primary endpoints: Total Body Water at 12 months and Percent Change in Total Kidney Volume at 2 years. Started Jan 2016; status: completed.
02
Drugs
pioglitazone
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT02697617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697617.